Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, presented new preclinical data for ciforadenant at the 2nd JCA-AACR Precision Cancer Medicine International Conference. The data highlights ciforadenant's mechanism of action and its synergy with immune checkpoint inhibitors. Corvus is currently conducting a Phase 1b/2 clinical trial to evaluate ciforadenant as a potential first-line therapy for metastatic renal cell cancer in combination with anti-CTLA-4 and anti-PD-1 therapies.
The presentation at the conference further supports the rationale for combining ciforadenant with checkpoint inhibitors to enhance the immune response against cancer. The ongoing clinical trial, led by the Kidney Cancer Research Consortium, is based on preclinical research demonstrating synergy between ciforadenant and anti-CTLA-4 and anti-PD-1 therapies. Initial data from the trial is expected to be shared before the end of 2023.
The new preclinical